Tactile Medical Q3 revenue up 24% to $65.3M; raises FY2022 guidance

TACTILE SYSTEMS TECHNOLOGY INC

2022-Q3 EPS reported -$1.12 revenue$172,885,000

Q3 revenue $65.3M (+24% YoY); net loss $2.3M ($0.11/sh) vs loss $3.4M ($0.17) a year ago.
Non-GAAP net income $1.9M vs non-GAAP loss $1.6M; Adjusted EBITDA $7.2M vs $4.1M.
Airway clearance revenue $11.0M (incl. AffloVest); lymphedema revenue up 5%.
Raises FY2022 revenue guidance to $242-245M (16-18% growth) from prior $238-242M.
Gross margin improved to 71.7% from 70.4%; cash $23.4M, debt $49.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TACTILE SYSTEMS TECHNOLOGY INC reported the third quarter and nine months ended September 30, 2022 results: revenue $65.3 million, net income $2.3 million, EPS $0.11 per diluted share. Guidance raised.

Period: the third quarter and nine months ended September 30, 2022
Revenue: $65.3 million
Net income: $2.3 million
EPS: $0.11 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

today reported financial results for the third quarter and nine months ended September 30, 2022. Third Quarter 2022 Summary: ● Total revenue increased 24% year-over-year to $65.3 million, compared to $52.5 million in third quarter 2021. ● Total revenue in third quarter 2022 included $11.0 million of revenue from sales of airway clearance products, which includes

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

TACTILE SYSTEMS TECHNOLOGY INC filing history →

Source: SEC EDGAR

accession 0001558370-22-016619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.